# A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients

> **NCT03560739** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 284 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **COMBINATION_PRODUCT:** ofatumumab with PRF
- **COMBINATION_PRODUCT:** ofatumumab with AI

## Key facts

- **NCT ID:** NCT03560739
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-11
- **Primary completion:** 2019-08-26
- **Final completion:** 2020-05-05
- **Target enrollment:** 284 (ACTUAL)
- **Last updated:** 2021-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03560739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03560739, "A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT03560739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*